Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
Article Details
- CitationCopy to clipboard
Kleinman EF, Campbell E, Giordano LA, Cohan VL, Jenkinson TH, Cheng JB, Shirley JT, Pettipher ER, Salter ED, Hibbs TA, DiCapua FM, Bordner J
Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
J Med Chem. 1998 Jan 29;41(3):266-70.
- PubMed ID
- 9464356 [ View in PubMed]
- Abstract
Not Available
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) (R)-Rolipram cAMP-specific 3',5'-cyclic phosphodiesterase 4B IC 50 (nM) 35.7 N/A N/A Details (R)-Rolipram cAMP-specific 3',5'-cyclic phosphodiesterase 4D IC 50 (nM) 31.6 N/A N/A Details Piclamilast cAMP-specific 3',5'-cyclic phosphodiesterase 4A IC 50 (nM) 1.6 N/A N/A Details Piclamilast cAMP-specific 3',5'-cyclic phosphodiesterase 4B IC 50 (nM) 1 N/A N/A Details Piclamilast cAMP-specific 3',5'-cyclic phosphodiesterase 4C IC 50 (nM) 3.8 N/A N/A Details Piclamilast cAMP-specific 3',5'-cyclic phosphodiesterase 4D IC 50 (nM) 0.8 N/A N/A Details